216 related articles for article (PubMed ID: 17627547)
1. Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets.
Iannucci CV; Capoccia D; Calabria M; Leonetti F
Curr Pharm Des; 2007; 13(21):2148-68. PubMed ID: 17627547
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy to reduce visceral fat.
Blackburn GL; Waltman BA
Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
[TBL] [Abstract][Full Text] [Related]
4. Cutoff values of body fat composition to predict metabolic risk factors with normal waist circumference in Asian Indian population.
Sureka B; George T; Garg MK; Banerjee M; Deora S; Sukhla R; Goel A; Garg PK; Yadav T; Khera PS
Eur Radiol; 2023 Jan; 33(1):711-719. PubMed ID: 35852580
[TBL] [Abstract][Full Text] [Related]
5. Epicardial adipose tissue is associated with visceral fat, metabolic syndrome, and insulin resistance in menopausal women.
Fernández Muñoz MJ; Basurto Acevedo L; Córdova Pérez N; Vázquez Martínez AL; Tepach Gutiérrez N; Vega García S; Rocha Cruz A; Díaz Martínez A; Saucedo García R; Zárate Treviño A; González Escudero EA; Degollado Córdova JA
Rev Esp Cardiol (Engl Ed); 2014 Jun; 67(6):436-41. PubMed ID: 24863591
[TBL] [Abstract][Full Text] [Related]
6. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance.
Mannerås-Holm L; Leonhardt H; Kullberg J; Jennische E; Odén A; Holm G; Hellström M; Lönn L; Olivecrona G; Stener-Victorin E; Lönn M
J Clin Endocrinol Metab; 2011 Feb; 96(2):E304-11. PubMed ID: 21084397
[TBL] [Abstract][Full Text] [Related]
7. Metabolic obesity: the paradox between visceral and subcutaneous fat.
Hamdy O; Porramatikul S; Al-Ozairi E
Curr Diabetes Rev; 2006 Nov; 2(4):367-73. PubMed ID: 18220642
[TBL] [Abstract][Full Text] [Related]
8. The combination of insulin resistance and visceral adipose tissue estimation improves the performance of metabolic syndrome as a predictor of type 2 diabetes.
Antonio-Villa NE; Bello-Chavolla OY; Vargas-Vázquez A; Mehta R; Aguilar-Salinas CA;
Diabet Med; 2020 Jul; 37(7):1192-1201. PubMed ID: 32061103
[TBL] [Abstract][Full Text] [Related]
9. The role of fat topology in the risk of disease.
Matsuzawa Y
Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S83-92. PubMed ID: 19136997
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?
Lemieux I; Poirier P; Bergeron J; Alméras N; Lamarche B; Cantin B; Dagenais GR; Després JP
Can J Cardiol; 2007 Oct; 23 Suppl B(Suppl B):23B-31B. PubMed ID: 17932584
[TBL] [Abstract][Full Text] [Related]
11. The metabolic syndrome - an ongoing story.
Duvnjak L; Duvnjak M
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():19-24. PubMed ID: 20388942
[TBL] [Abstract][Full Text] [Related]
12. Associations between ultrasound measures of abdominal fat distribution and indices of glucose metabolism in a population at high risk of type 2 diabetes: the ADDITION-PRO study.
Philipsen A; Jørgensen ME; Vistisen D; Sandbaek A; Almdal TP; Christiansen JS; Lauritzen T; Witte DR
PLoS One; 2015; 10(4):e0123062. PubMed ID: 25849815
[TBL] [Abstract][Full Text] [Related]
13. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
[TBL] [Abstract][Full Text] [Related]
14. Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis.
Wanderley Rocha DR; Jorge AR; Braulio VB; Arbex AK; Marcadenti A
Curr Diabetes Rev; 2017; 13(1):11-18. PubMed ID: 26467189
[TBL] [Abstract][Full Text] [Related]
15. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships.
Zamboni M; Armellini F; Milani MP; De Marchi M; Todesco T; Robbi R; Bergamo-Andreis IA; Bosello O
Int J Obes Relat Metab Disord; 1992 Jul; 16(7):495-504. PubMed ID: 1323546
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a concept of visceral fat syndrome and discovery of adiponectin.
Matsuzawa Y
Proc Jpn Acad Ser B Phys Biol Sci; 2010; 86(2):131-41. PubMed ID: 20154470
[TBL] [Abstract][Full Text] [Related]
17. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?
Rodríguez A; Catalán V; Gómez-Ambrosi J; Frühbeck G
Curr Pharm Des; 2007; 13(21):2169-75. PubMed ID: 17627548
[TBL] [Abstract][Full Text] [Related]
18. High adipose LPL activity and adipocyte hypertrophy reduce visceral fat and metabolic risk in obese, older women.
Serra MC; Ryan AS; Sorkin JD; Favor KH; Goldberg AP
Obesity (Silver Spring); 2015 Mar; 23(3):602-7. PubMed ID: 25612068
[TBL] [Abstract][Full Text] [Related]
19. Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome.
Echiburú B; Pérez-Bravo F; Galgani JE; Sandoval D; Saldías C; Crisosto N; Maliqueo M; Sir-Petermann T
Steroids; 2018 Feb; 130():15-21. PubMed ID: 29273198
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome, a cardiovascular disease risk factor: role of adipocytokines and impact of diet and physical activity.
Robinson LE; Graham TE
Can J Appl Physiol; 2004 Dec; 29(6):808-29. PubMed ID: 15630152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
